Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

The build vs. outsource decision is strategic. Building in-house is justified when manufacturing is a core competitive advantage or the process itself is your key IP. Otherwise, outsourcing to a CDMO offers critical speed to clinic and preserves capital.

A key learning from Newscom's personalized vaccine trials was not just clinical validation, but the realization that "your process is your product." This insight shifted their strategic focus towards automating and optimizing the manufacturing system to significantly reduce production costs, making the on-demand therapy commercially viable and accessible.

The belief that bioprocess development must take a long time becomes a self-fulfilling prophecy. Professor Waranyoo Phoolcharoen argues that integrating manufacturing, scalability, and downstream constraints from day one can significantly shorten timelines, challenging the industry's traditional, sluggish mindset.

MRM Health's founder, Sam Possemiers, leveraged his profitable Contract Research Organization (CRO), Prodigest, to finance the entire seed stage of his new biotech venture. Reinvesting proceeds into technology development allowed MRM to de-risk its platform for five years without taking on early-stage dilutive funding.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

A 'healthy tension' exists between research teams, who want to continually iterate on a therapy's design, and manufacturing teams, who need a finalized process to scale production for trials. Knowing precisely when to 'lock down' the design is a critical, yet difficult, decision point for successful commercialization.